Should I Buy INBX? INBX 2026 Analysis

Should You Buy Inhibrx Biosciences Inc (INBX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

83.910

1 Day change

2.92%

52 Week Range

94.560

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the chart trend is bullish, but there’s no Intellectia buy signal and price is sitting just below a key resistance zone while earnings are very close.
For an impatient buyer, the risk/reward is unattractive into the 2026-02-13 pre-market earnings event given weak recent financial trends (continued losses) and no fresh news catalyst.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bullish structure (SMA_5 > SMA_20 > SMA_200) indicates an established uptrend.
Momentum: MACD histogram +1.252 and expanding = positive momentum still intact despite today’s pullback.
RSI: RSI_6 = 65.2 (neutral-to-slightly-warm), not yet “overbought,” but not a washed-out dip either.
Levels: Pivot support ~78.62 is the first meaningful “buy-the-dip” area; near-term resistance is R1 ~85.26 (very close to prior close area) and then R2 ~89.35.
Price action context: Closed at 82.63 (-2.96%)—a pullback within an uptrend, but not at a clear technical bargain level.
Pattern-based odds: Similar-pattern projection suggests ~~+1.41% next week and ~+4.7% next month, but slightly negative next day (~~-0.64%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call ratio = 0.18 (call-heavy), generally bullish sentiment/positioning.
Flow today: Option volume is extremely low (only 6 total; 0 puts), so today’s tape is not very informative despite the bullish skew.
Volatility: 30D IV ~87.6% vs HV ~63.4% (options still pricing significant event risk), but IV percentile ~8 and IV rank ~13 suggest IV is low relative to its own history (options “cheaper than usual” vs prior months).
IV trend: IV has dropped vs 5D/10D averages (116/125), implying event premium cooled recently—could re-expand into earnings.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical trend remains bullish (stacked moving averages + positive MACD).
- Call-heavy options open interest (low put/call OI ratio) implies bullish positioning.
- Potential pre-earnings volatility/run-up catalyst with earnings on 2026-02-13 (pre-market).
- IV percentile/rank are low vs history, which can make directional options relatively cheaper if a catalyst is expected.

Neutral/Negative Catalysts

- Event risk: Earnings in ~1 week (2026-02-13 pre-market) can trigger gap moves; hard to time for an impatient entry.
- No news in the last week: no clear event-driven catalyst supporting an immediate upside push.
- Options liquidity/confirmation is weak today (volume far below 5D/10D averages), reducing confidence in sentiment read.
- Price is not at support (pivot ~78.62); buying here risks a mean-reversion dip without a clear technical “discount.”

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: reported as 0 (no meaningful revenue base).
Profitability: Net loss widened to -$35.256M (down ~19.6% YoY); EPS -2.28 (down ~19.7% YoY) — losses are getting worse.
Takeaway: Financial trend is negative (deepening losses) and does not support an “easy” conviction buy right now heading into earnings.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided here, so there is no confirmed recent Wall Street upgrade/downgrade or target revision trend to lean on.
Wall Street-style pros view (typical for development biotechs): upside optionality tied to pipeline/clinical milestones and event-driven repricing.
Wall Street-style cons view: limited/zero revenue base and widening losses increase reliance on catalysts and future financing; risk is concentrated around binary events (like earnings/updates).

Analyst Rating

Wall Street analysts forecast INBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 81.530

Low

Averages

High

Current: 81.530

Low

Averages

High

Citizens Capital Markets

Reni Benjamin

Hold

Reiterates

n/a

AI Analysis

2025-03-18

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

n/a

AI Analysis

2025-03-18

Reiterates

Hold

Reason

INBX Should I Buy

INBX Should I Buy

Should You Buy Inhibrx Biosciences Inc (INBX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch